NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reiterated at D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $31.00 target price on the stock.

Several other brokerages also recently weighed in on NRXP. HC Wainwright restated a “buy” rating and issued a $19.00 target price on shares of NRx Pharmaceuticals in a research note on Friday, March 14th. Ascendiant Capital Markets raised their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd.

NRx Pharmaceuticals Stock Performance

Shares of NASDAQ:NRXP opened at $2.20 on Monday. The firm has a market cap of $37.22 million, a PE ratio of -1.03 and a beta of 1.22. The firm’s 50 day simple moving average is $2.94 and its 200-day simple moving average is $2.02. NRx Pharmaceuticals has a one year low of $1.10 and a one year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). Equities research analysts predict that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in NRXP. Townsquare Capital LLC purchased a new position in shares of NRx Pharmaceuticals during the third quarter worth $25,000. Sassicaia Capital Advisers LLC purchased a new position in NRx Pharmaceuticals in the fourth quarter valued at $33,000. Squarepoint Ops LLC purchased a new position in NRx Pharmaceuticals in the fourth quarter valued at $56,000. Millennium Management LLC purchased a new position in NRx Pharmaceuticals in the fourth quarter valued at $61,000. Finally, Anson Funds Management LP purchased a new position in NRx Pharmaceuticals in the third quarter valued at $241,000. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.